82_FR_40940 82 FR 40775 - Government-Owned Inventions; Availability for Licensing

82 FR 40775 - Government-Owned Inventions; Availability for Licensing

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 82, Issue 165 (August 28, 2017)

Page Range40775-40776
FR Document2017-18137

The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

Federal Register, Volume 82 Issue 165 (Monday, August 28, 2017) 
[Federal Register Volume 82, Number 165 (Monday, August 28, 2017)]
[Notices]
[Pages 40775-40776]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-18137]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Chris Kornak, 240-627-3705, 
[email protected]. Licensing information and copies of the U.S. 
patent applications listed below may be obtained by communicating with 
the indicated licensing contact at the Technology Transfer and 
Intellectual Property Office, National Institute of Allergy and 
Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301-
496-2644. A signed Confidential Disclosure Agreement will be required 
to receive copies of unpublished patent applications.

SUPPLEMENTARY INFORMATION: Technology description follows.

HIV Targets CD62L on Central Memory T Cells Through Viral Envelope 
Glycans for Adhesion and Induces Selectin Shedding for Viral Release

Description of Technology

    Despite the success of anti-retroviral therapy in controlling HIV 
in infected individuals, treatment is less effective at eliminating HIV 
viral reservoirs. The nature of HIV reservoirs and the factors 
controlling their size and release are a major research focus for 
achieving a cure for HIV/AIDS.
    NIAID researchers have identified L-selectin/CD62L as a new target 
for treating HIV by inhibiting viral release from infected cells. They 
found that shedding of CD62L on T cells is required for the efficient 
release of HIV virus from infected cells. Further, they have shown that 
inhibition of CD62L shedding dramatically reduced HIV-1 infection and 
viral release from both viremic and aviremic CD4+ T cells. Therefore, 
inhibitors for CD62L sheddase can function as an anti-HIV treatment 
that may be effective alone or in combination with existing 
therapeutics.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as 
well as for further development and evaluation under a research 
collaboration.

Potential Commercial Applications

     New target for HIV therapeutic development.

[[Page 40776]]

Competitive Advantages

     This invention comprises a method of treating HIV using 
therapeutics geared toward viral release and entry, distinguishing it 
from other antiviral candidates with its method of action.
     CD62L is a new target for HIV

Development Stage

     In vitro studies; Proof-of-concept studies.

Inventors

Peter Sun, NIAID, NIH
Joseph Kononchik, NIAID, NIH
Joanna Ireland, NIAID, NIH
Ruiping Wang, NIAID, NIH

    Intellectual Property: HHS Reference No. E-261-2015/0--PCT No. PCT/
US2016/068713 filed 12/27/2016.
    Licensing Contact: Chris Kornak, 240-627-3705, 
[email protected].
    Collaborative Research Opportunity: The Technology Transfer and 
Intellectual Property Office (TTIPO) is seeking parties interested in 
collaborative research to further co-develop this technology by 
identifying pharmacological compounds inhibiting CD62L shedding by 
using high throughput compound screening. For collaboration 
opportunities, please contact Chris Kornak, 240-627-3705, 
[email protected].

    Dated: August 15, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2017-18137 Filed 8-25-17; 8:45 am]
BILLING CODE 4140-01-P

Federal Register / Vol. 82, No. 165 / Monday, August 28, 2017 / Notices 40775 There will be a final report that is policy recommendations, and future the assessment geography, key leaders thematically organized and describes research. and stakeholders across a variety of key findings and strategic Likely Respondents: Data for this governmental and non-governmental recommendations for Region VIII assessment will be collected through sectors. OASH/OWH to consider supporting three mechanisms—a survey of women The total annual burden hours future evidence-based program living in the assessment geography, focus groups with a cross-section of estimated for this ICR are summarized development and implementation, in the table below. women and other key groups living in TOTAL ESTIMATED ANNUALIZED BURDEN—HOURS Average Number of Number of burden per Total burden Form name responses per respondents response hours respondent (in hours) Community Survey .......................................................................................... 500 1 15/60 125 Focus Groups .................................................................................................. 240 1 90/60 360 Interviews ......................................................................................................... 40 1 60/60 40 Total .......................................................................................................... 780 1 40.4/60 525 Terry S. Clark, (Catalogue of Federal Domestic Assistance 301–496–2644. A signed Confidential Asst Information Collection Clearance Program Nos. 93.855, Allergy, Immunology, Disclosure Agreement will be required Officer. and Transplantation Research; 93.856, to receive copies of unpublished patent Microbiology and Infectious Diseases [FR Doc. 2017–18117 Filed 8–25–17; 8:45 am] applications. Research, National Institutes of Health, HHS) BILLING CODE 4150–33–P SUPPLEMENTARY INFORMATION: Dated: August 22, 2017. Technology description follows. Natasha M. Copeland, DEPARTMENT OF HEALTH AND HIV Targets CD62L on Central Memory Program Analyst, Office of Federal Advisory T Cells Through Viral Envelope HUMAN SERVICES Committee Policy. Glycans for Adhesion and Induces National Institutes of Health [FR Doc. 2017–18121 Filed 8–25–17; 8:45 am] Selectin Shedding for Viral Release BILLING CODE 4140–01–P National Institute of Allergy and Description of Technology Infectious Diseases; Notice of Closed Despite the success of anti-retroviral Meeting DEPARTMENT OF HEALTH AND therapy in controlling HIV in infected HUMAN SERVICES individuals, treatment is less effective at Pursuant to section 10(d) of the Federal Advisory Committee Act, as eliminating HIV viral reservoirs. The National Institutes of Health amended, notice is hereby given of the nature of HIV reservoirs and the factors following meeting. Government-Owned Inventions; controlling their size and release are a The meeting will be closed to the Availability for Licensing major research focus for achieving a public in accordance with the cure for HIV/AIDS. provisions set forth in sections AGENCY: National Institutes of Health, NIAID researchers have identified L- 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., HHS. selectin/CD62L as a new target for as amended. The contract proposals and ACTION: Notice. treating HIV by inhibiting viral release the discussions could disclose from infected cells. They found that SUMMARY: The inventions listed below shedding of CD62L on T cells is confidential trade secrets or commercial are owned by an agency of the U.S. required for the efficient release of HIV property such as patentable material, Government and are available for virus from infected cells. Further, they and personal information concerning licensing to achieve expeditious have shown that inhibition of CD62L individuals associated with the contract commercialization of results of shedding dramatically reduced HIV–1 proposals, the disclosure of which federally-funded research and infection and viral release from both would constitute a clearly unwarranted development. Foreign patent viremic and aviremic CD4+ T cells. invasion of personal privacy. applications are filed on selected Therefore, inhibitors for CD62L Name of Committee: National Institute of inventions to extend market coverage Allergy and Infectious Diseases Special sheddase can function as an anti-HIV for companies and may also be available treatment that may be effective alone or Emphasis Panel NIAID Peer Review Meeting. Date: September 20–21, 2017. for licensing. in combination with existing Time: 12:00 p.m. to 4:00 p.m. FOR FURTHER INFORMATION CONTACT: therapeutics. Agenda: To review and evaluate contract Chris Kornak, 240–627–3705, This technology is available for asabaliauskas on DSKBBXCHB2PROD with NOTICES proposals. Chris.Kornak@nih.gov. Licensing licensing for commercial development Place: National Institutes of Health, 5601 information and copies of the U.S. in accordance with 35 U.S.C. 209 and 37 Fishers Lane, Rockville, MD 20892, patent applications listed below may be CFR part 404, as well as for further (Telephone Conference Call). obtained by communicating with the development and evaluation under a Contact Person: Kelly Y. Poe, Ph.D., Scientific Review Program, Division of indicated licensing contact at the research collaboration. Extramural Activities, Room 3F40B, National Technology Transfer and Intellectual Property Office, National Institute of Potential Commercial Applications Institutes of Health, NIAID, 5601 Fishers Lane, MSC 9823, Bethesda, MD 20892–9823, Allergy and Infectious Diseases, 5601 • New target for HIV therapeutic (240) 669–5036, poeky@mail.nih.gov. Fishers Lane, Rockville, MD 20852; tel. development. VerDate Sep<11>2014 18:45 Aug 25, 2017 Jkt 241001 PO 00000 Frm 00032 Fmt 4703 Sfmt 4703 E:\FR\FM\28AUN1.SGM 28AUN1

40776 Federal Register / Vol. 82, No. 165 / Monday, August 28, 2017 / Notices Competitive Advantages additional two-year period on August DEPARTMENT OF HEALTH AND • This invention comprises a method 15, 2017. HUMAN SERVICES of treating HIV using therapeutics Inquiries may be directed to Jennifer Spaeth, Director, Office of Federal National Institutes of Health geared toward viral release and entry, distinguishing it from other antiviral Advisory Committee Policy, Office of Proposed Collection: 60-Day Comment candidates with its method of action. the Director, National Institutes of Request; Generic Clearance To • CD62L is a new target for HIV Health, 6701 Democracy Boulevard, Support the Safe to Sleep® Campaign Suite 1000, Bethesda, Maryland 20892 at the Eunice Kennedy Shriver National Development Stage (Mail code 4875), Telephone (301) 496– Institute for Child Health and Human • In vitro studies; Proof-of-concept 2123, or spaethj@od.nih.gov. Development (NICHD) studies. Dated: August 18, 2017. AGENCY: National Institutes of Health, Inventors Jennifer Spaeth, HHS. Peter Sun, NIAID, NIH Director, Office of Federal Advisory ACTION: Notice. Joseph Kononchik, NIAID, NIH Committee Policy. [FR Doc. 2017–18197 Filed 8–25–17; 8:45 am] SUMMARY: In compliance with the Joanna Ireland, NIAID, NIH requirement of the Paperwork Ruiping Wang, NIAID, NIH BILLING CODE 4140–01–P Reduction Act of 1995 to provide Intellectual Property: HHS Reference opportunity for public comment on No. E–261–2015/0—PCT No. PCT/ proposed data collection projects, the US2016/068713 filed 12/27/2016. DEPARTMENT OF HEALTH AND HUMAN SERVICES Eunice Kennedy Shriver National Licensing Contact: Chris Kornak, 240– Institute of Child Health and Human 627–3705, Chris.Kornak@nih.gov. National Institutes of Health Development (NICHD), the National Collaborative Research Opportunity: Institutes of Health (NIH) will publish The Technology Transfer and National Institute on Aging; Notice of periodic summaries of proposed Intellectual Property Office (TTIPO) is Closed Meeting projects to be submitted to the Office of seeking parties interested in Management and Budget (OMB) for collaborative research to further co- Pursuant to section 10(d) of the review and approval. develop this technology by identifying Federal Advisory Committee Act, as DATES: Comments regarding this pharmacological compounds inhibiting amended, notice is hereby given of the information collection are best assured CD62L shedding by using high following meeting. of having their full effect if received throughput compound screening. For within 60 days of the date of this The meeting will be closed to the collaboration opportunities, please publication. public in accordance with the contact Chris Kornak, 240–627–3705, provisions set forth in sections FOR FURTHER INFORMATION CONTACT: To Chris.Kornak@nih.gov. 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., obtain a copy of the data collection Dated: August 15, 2017. as amended. The grant applications and plans and instruments, submit Suzanne Frisbie, the discussions could disclose comments in writing, or request more Deputy Director, Technology Transfer and confidential trade secrets or commercial information on the proposed project, Intellectual Property Office, National Institute property such as patentable material, contact: Lorena Kaplan, M.P.H., CHES, of Allergy and Infectious Diseases. and personal information concerning Office of Communications, Eunice [FR Doc. 2017–18137 Filed 8–25–17; 8:45 am] individuals associated with the grant Kennedy Shriver National Institute of BILLING CODE 4140–01–P applications, the disclosure of which Child Health and Human Development, would constitute a clearly unwarranted National Institutes of Health, 31 Center invasion of personal privacy. Drive, Room 2A32, Bethesda, Maryland DEPARTMENT OF HEALTH AND 20892, or call non-toll free number (301) Name of Committee: National Institute on HUMAN SERVICES 496–6670 or Email your request, Aging Initial Review Group; Behavior and Social Science of Aging Review Committee. including your address to National Institutes of Health lorena.kaplan@nih.gov. Formal requests Date: October 5–6, 2017. Time: 3:00 p.m. to 2:00 p.m. for additional plans and instruments Office of the Director; Notice of Charter Agenda: To review and evaluate grant must be requested in writing. Renewal applications. SUPPLEMENTARY INFORMATION: Section It is determined that the Advisory Place: Bethesda Marriott, 5151 Pooks Hill 3506(c)(2)(A) of the Paperwork Committee to the Deputy Director for Road, Bethesda, MD 20814. Reduction Act of 1995 requires: Written Intramural Research, National Institutes Contact Person: Kimberly Firth, Ph.D., comments and/or suggestions from the of Health, is in the public interest in National Institute on Aging, Gateway public and affected agencies are invited connection with the performance of Building, 7201 Wisconsin Avenue, Suite to address one or more of the following duties imposed on the National 2C212, Bethesda, MD 20892, 301–402–7702, points: (1) Whether the proposed Institutes of Health by law, and that kimberly.firth@nih.gov. collection of information is necessary these duties can best be performed (Catalogue of Federal Domestic Assistance for the proper performance of the asabaliauskas on DSKBBXCHB2PROD with NOTICES through the advice and counsel of this Program Nos. 93.866, Aging Research, function of the agency, including group. National Institutes of Health, HHS) whether the information will have In accordance with Title 41 of the practical utility; (2) the accuracy of the Dated: August 23, 2017. U.S. Code of Federal Regulations, agency’s estimate of the burden of the Section 102–3.65(a), notice is hereby Melanie J. Pantoja, proposed collection of information, given that the Charter for the Advisory Program Analyst, Office of Federal Advisory including the validity of the Committee to the Deputy Director for Committee Policy. methodology and assumptions used; (3) Intramural Research, National Institutes [FR Doc. 2017–18199 Filed 8–25–17; 8:45 am] ways to enhance the quality, utility, and of Health, was renewed for an BILLING CODE 4140–01–P clarity of the information to be VerDate Sep<11>2014 18:45 Aug 25, 2017 Jkt 241001 PO 00000 Frm 00033 Fmt 4703 Sfmt 4703 E:\FR\FM\28AUN1.SGM 28AUN1


Document Created: 2017-08-28 11:30:32
Document Modified: 2017-08-28 11:30:32
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
ActionNotice.
ContactChris Kornak, 240-627-3705, [email protected] Licensing information and copies of the U.S. patent applications listed below may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301- 496-2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications.
FR Citation82 FR 40775 
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR